HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part II. Vector Systems and Applications

Neoplasia

Volumn 1, Issue 5, 1999, Pages 402-416

  Jacobs, Andreas ^a,b,d   Breakefield, Xandra O ^b   Fraefel, Cornel ^b,c  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Amplicon; Gene therapy; Glioma; Recombinant HSV 1

Indexed keywords

BIOLOGICAL MODEL; BRAIN TUMOR; GENE THERAPY; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS 1; HUMAN; METABOLISM; METHODOLOGY; NERVE CELL; NEUROLOGIC DISEASE; REVIEW; VIRUS GENE;

BRAIN NEOPLASMS; GENE THERAPY; GENES, VIRAL; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MODELS, GENETIC; NERVOUS SYSTEM DISEASES; NEURONS;

EID: 0033222932     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900056     Document Type: Review

References (202)

1. Post LE, and Roizman B (1981). A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth. Cell 25, 227-232.
2. Herrlinger U, Jacobs A, Aghi M, and Breakefield XO (1999). HSV-1 Vectors for Therapy of Experimental CNS Tumors. In: Methods in Molecular Medicine, Gene Therapy Protocols. Robins P (Ed.). Humana Press, Totowa, NJ, in press.
3. Krisky DM, Marconi PC, Oligino T, Rouse RJ, Fink DJ, and Glorioso JC (1997). Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 4, 1120-1125.
4. Fink DJ, and Glorioso JC (1997). Engineering herpes simplex virus vectors for gene transfer to neurons. Nat Med 3, 357-359.
5. Chiocca EA, Choi BB, Cai WZ, DeLuca NA, Schaffer PA, DiFiglia M, Breakefield XO, and Martuza RL (1990). Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol 2, 739-746.
6. DeLuca NA, McCarthy AM, and Schaffer PA (1985). Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 56, 558-570.
7. Glorioso JC, DeLuca NA, and Fink DJ (1995). Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol 49, 675-710.
8. Johnson PA, Miyanohara A, Levine F, Cahill T, and Friedmann T (1992). Cytotoxicity of a replication - defective mutant of herpes simplex virus type 1. J Virol 66, 2952-2965.
9. Russell J, Stow ND, Stow EC, and Preston CM (1987). Herpes simplex virus genes involved in latency in vitro. J Gen Virol 68, 3009-3018.
10. Johnson PA, Wang MJ, and Friedmann T (1994). Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function. J Virol 68, 6347-6362.
11. Krisky DM, Marconi PC, Oligino TJ, Rouse RJ, Fink DJ, Cohen JB, Watkins SC, and Glorioso JC (1998). Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther 5, 1517-1530.
12. Krisky DM, Wolfe D, Goins WF, Marconi PC, Ramakrishnan R, Mata M, Rouse RJ, Fink DJ, and Glorioso JC (1998). Deletion of multiple immediate - early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther 5, 1593-1603.
13. Marconi P, Krisky D, Oligino T, Poliani PL, Ramakrishnan R, Goins WF, Fink DJ, and Glorioso JC (1996). Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc NatlAcad Sci USA 93, 11319-11320.
14. Wu N, Watkins SC, Schaffer PA, and DeLuca NA (1996). Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J Virol 70, 6358-6369.
15. Samaniego LA, Wu N, and DeLuca NA (1997). The herpes simplex virus immediate-early protein ICPO affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 71, 4614-4625.
16. Preston CM, and Nicholl MJ (1997). Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants impaired for immediate-early protein synthesis. J Virol 71, 7807-7813.
17. Preston CM, Mabbs R, and Nicholl MJ (1997). Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression. Virology 229, 228-239.
18. Samaniego LA, Neiderhiser L, and DeLuca NA (1998). Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 72, 3307-3320.
19. Yamada M, Oligino T, Mata M, Goss JR, Glorioso JC, and Fink DJ (1999). Herpes simplex virus vector-mediated expression of bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 96, 4078-4083.
20. Chou J, Kern ER, Whitley RJ, and Roizman B (1990). Mapping of herpes simplex virus-1 neurovirulence to 34.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
21. Whitley RJ, Kern ER, Chatterjee S, Chou J, and Roizman B (1993). Replication, establishment of latency, and induced reactivation of herpes simplex virus 34.5 deletion mutants in rodent models. J Clin Invest 91, 2837-2843.
22. Markert JM, Malick A, Coen DM, and Martuza RL (1993). Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32, 597-603.
23. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B, and Whitley RJ (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a seid mouse model of human malignant glioma. Proc Natl Acad Sci USA 92, 1411-1415.
24. Coffin RS, MacLean AR, Latchman DS, and Brown SM (1996). Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors. Gene Ther 3, 886-891.
25. Wagstaff MJ, Smith J, Collaco-Moraes Y, de Belleroche JS, Voellmy R, Coffin RS, and Latchman DS (1998). Delivery of a constitutively active form of the heat shock factor using a virus vector protects neuronal cells from thermal or ischaemic stress but not from apoptosis. Eur J Neurosci 10, 3343-3350.
26. Wagstaff MJ, Collaco-Moraes Y, Smith J, de Belleroche JS, Coffin RS, and Latchman DS (1999). Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector. J Biol Chem 274, 5061-5069.
27. Howard MK, Coffin RS, MacLean AR, Brown SM, Bailey D, Anderson PN, Bumstock G, and Latchman DS (1997). Gene delivery to rat enteric neurons using herpes simplex virus-based vectors. J Mol Neurosci 9, 65-74.
28. Batchelor AH, and O'Hare P (1990). Regulation and cell-type-specific activity of a promoter located upstream of the latency-associated transcript of herpes simplex virus type 1. J Virol 64, 3269-3279.
29. Zwaagstra JC, Ghiasi H, Slanina SM, Nesburn AB, Wheatley SC, Lillycrop K, Wood J, Latchman DS, Patel K, and Wechsler SL (1990). Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript. J Virol 64, 5019-5028.
30. Ho DY, and Mocarski ES (1989). Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse. Proc NatlAcad Sci USA 86, 7596-7600.
31. Lachmann RH, and Efstathiou S (1997). Utilization of the herpes simplex virus type 1 latency-associated regulatory region to drive stable reporter gene expression in the nervous system. J Virol 71, 3197-3207.
32. Wolfe JH, Deshmane SL, and Fraser NW (1992). Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice. Nat Genet 1, 379-384.
33. Goins WF, Sternberg LR, Croen KD, Krause PR, Hendricks RL, Fink DJ, Straus SE, Levine M, and Glorioso JC (1994). A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol 68, 2239-2252.
34. Goins WF, Lee KA, Cavalcoli JD, O'Malley ME, DeKosky ST, Fink DJ, and Glorioso JC (1999). Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J Virol 73, 519-532.
35. Andersen JK, Frim DM, Isacson O, and Breakefield XO (1993). Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cell Mol Neurobiol 13, 503-515.
36. Fink DJ, Sternberg LR, Weber PC, Mata M, Goins WF, and Glorioso JC (1992). In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum Gene Ther 3, 11-19.
37. Lokensgard JR, Bloom DC, Dobson AT, and Feldman LT (1994). Long-term promoter activity during herpes simplex virus latency. J Virol 68, 7148-7158.
38. Carpenter DE, and Stevens JG (1996). Long-term expression of a foreign gene from a unique position in the latent herpes simplex virus genome. Hum Gene Ther 7, 1447-1454.
39. Dobson AT, Margolis TP, Sedarati F, Stevens JG, and Feldman LT (1990). A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons. Neuron 5, 353-360.
40. Moolten FL (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46, 5276-5281.
41. Mullen CA, Kilstrup M, and Blaese RM (1992). Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 69, 33-37.
42. Aghi M, Kramm CM, Chou TC, Breakefield XO, and Chiocca EA (1998). Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 90, 370-380.
43. Mroz PJ, and Moolten FL (1993). Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum Gene Ther 4, 589-595.
44. Tamiya T, Ono Y, Wei MX, Mroz PJ, Moolten FL, and Chiocca EA (1996). Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther 3, 155-162.
45. Chen L, and Waxman DJ (1995). Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55, 581-589.
46. Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, Hilton J, Chiocca EA, and Breakefield XO (1998). New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther 9, 1261-1273.
47. Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TK, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, and Chiocca EA (1994). Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 5, 969-978.
48. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, and Fine HA (1996). Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 2, 567-573.
49. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, and Cai D (1996). Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2, 985-991.
50. Chung RY, and Chiocca EA (1998). Gene therapy for tumors of the central nervous system. Surg Oncol Clin N Am 7, 589-602.
51. Ho DY, and Mocarski ES (1988). Beta-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infected mouse. Virology 167, 279-283.
52. Markert JM, Coen DM, Malick A, Mineta T, and Martuza RL (1992). Expanded spectrum of viral therapy in the treatment of nervous system tumors. J Neurosurg 77, 590-594.
53. Martuza RL, Malick A, Markert JM, Ruffner KL, and Coen DM (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
54. Jia WW, McDermott M, Goldie J, Cynader M, Tan J, and Tufaro F (1994). Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 86, 1209-1215.
55. Jia WW, Tan J, Redekop GJ, and Goldie JH (1996). Toxicity studies in thymidine kinase-deficient herpes simplex virus therapy for malignant astrocytoma. J Neurosurg 85, 662-666.
56. Miyatake S, Iyer A, Martuza RL, and Rabkin SD (1997). Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 71, 5124-5132.
57. Kaplitt MG, Tjuvajev JG, Leib DA, Berk J, Pettigrew KD, Posner JB, Pfaff DW, Rabkin SD, and Blasberg RG (1994). Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neurooncol 19, 137-147.
58. Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, and Chiocca EA (1994). Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1, 323-331.
59. Boviatsis EJ, Chase M, Wei MX, Tamiya T, Hurford RKJ, Kowall NW, Tepper RI, Breakefield XO, and Chiocca EA (1994). Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther 5, 183-191.
60. Boviatsis EJ, Park JS, Sena - Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakefield XO, and Chiocca EA (1994). Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 54, 5745-5751.
61. Goldstein DJ, and Weller SK (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62, 196-205.
62. Mineta T, Rabkin SD, and Martuza RL (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54, 3963-3966.
63. Brown SM, Harland J, MacLean AR, Podlech J, and Clements JB (1994). Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J Gen Virol 75, 2367-2377.
64. MacLean AR, ul-Fareed M, Robertson L, Harland J, and Brown SM (1991). Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 72, 631-639.
65. McKie EA, MacLean AR, Lewis AD, Cruickshank G, Rampling R, Barnett SC, Kennedy PG, and Brown SM (1996). Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapy. Br J Cancer 74, 745-752.
66. Mineta T, Rabkin SD, Yazaki T, Hunter WD, and Martuza RL (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938-943.
67. Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, and Breakefield XO (1997). Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 8, 2057-2068.
68. Pyles RB, Warnick RE, Chalk CL, Szanti BE, and Parysek LM (1997). A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 8, 533-544.
69. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, and Whitley RJ (1997). Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57, 1502-1509.
70. Kesari S, Randazzo BP, Valyi-Nagy T, Huang QS, Brown SM, MacLean AR, Lee VM, Trojanowski JQ, and Fraser NW (1995). Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 73, 636-648.
71. Lasner TM, Kesari S, Brown SM, Lee VM, Fraser NW, and Trojanowski JQ (1996). Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol 55, 1259-1269.
72. Randazzo BP, Kesari S, Gesser RM, Alsop D, Ford JC, Brown SM, MacLean A, and Fraser NW (1995). Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211, 94-101.
73. McKie EA, Brown SM, MacLean AR, and Graham DI (1998). Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV-1): relevance for gene and cancer therapy. Neuropathol Appl Neurobiol 24, 367-372.
74. Rampling R, Cruickshank G, MacLean A, and Brown M (1998). Therapeutic replication-competent herpes virus. Nat Med 4, 133.
75. Markovitz NS, Baunoch D, and Roizman B (1997). The range and distribution of murine central nervous system cells infected with the gamma(1)34.5-mutant of herpes simplex virus 1. J Virol 71, 5560-5569.
76. Kesari S, Lasner TM, Balsara KR, Randazzo BP, Lee VM, Trojanowski JQ, and Fraser NW (1998). A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J Gen Virol 79, 525-536.
77. McMenamin MM, Byrnes AP, Charlton HM, Coffin RS, Latchman DS, and Wood MJ (1998). A gamma 34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 83, 1225-1237.
78. McMenamin MM, Byrnes AP, Pike FG, Charlton HM, Coffin RS, Latchman DS, and Wood MJ (1998). Potential and limitations of a gamma 34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS. Gene Ther 5, 594-604.
79. Lasner TM, Tal-Singer R, Kesari S, Lee VM, Trojanowski JQ, and Fraser NW (1998). Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J Neurovirol 4, 100-105.
80. Andreansky S, He B, van Cott J, McGhee J, Marken JM, Gillespie GY, Roizman B, and Whitley RJ (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5, 121-130.
81. Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B, and Weichselbaum RR (1998). Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther 5, 160-165.
82. Carroll NM, Chiocca EA, Takahashi K, and Tanabe KK (1996). Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 224, 323-329.
83. Kramm CM, Rainov NG, Sena-Esteves M, Barnett FH, Chase M, Herrlinger U, Pechan PA, Chiocca EA, and Breakefield XO (1996). Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther 7, 1989-1994.
84. Kramm CM, Rainov NG, Sena-Esteves M, Chase M, Pechan PA, Chiocca EA, and Breakefield XO (1996). Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther 7, 291-300.
85. Jacobs A, Tjuvajev JG, Balatoni J, Herrlinger U, Joshi R, Pechan PA, Finn R, Chiocca EA, Breakefield XO, and Blasberg RG (1999). Imaging HSV-1 vector replication and gene delivery in vivo. J Gene Med 01, 15.
86. Chase M, Chung RY, and Chiocca EA (1998). An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 16, 444-448.
87. Aghi M, Chou TC, Suling K, Breakefield XO, and Chiocca EA (1999). Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/CYP2B1 and ganciclovir/HSV-TK gene therapies. Cancer Res in press.
88. Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, Pechan PA, Barth RF, Finkelstein D, Chiocca EA, Louis DN, and Breakefield XO (1998). Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther 5, 809-819.
89. Wang Q, Guo J. and Jia W (1997). Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. Gene Ther 4, 1300-1304.
90. Yazaki T, Manz HJ, Rabkin SD, and Martuza RL (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55, 4752-4756.
91. Coen DM, Goldstein DJ, and Weller SK (1989). Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob. Agents Chemother 33, 1395-1399.
92. Toda M, Rabkin SD, and Martuza RL (1998). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9, 2177-2185.
93. Toda M, Rabkin SD, Kojima H, and Martuza RL (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10, 385-393.
94. Martuza RL (1997). Act locally, think globally. Nat Med 3, 1323.
95. Frenkel N, Locker H, Batterson W, Hayward GS, and Roizman B (1976). Anatomy of herpes simplex virus DMA. VI. Defective DNA originates from the S component. J Virol 20, 527-531.
96. Locker H, and Frenkel N (1979). Structure and origin of defective genomes contained in serially passaged herpes simplex virus type 1 (Justin). J Virol 29, 1065-1077.
97. Locker H, Frenkel N, and Halliburton I (1982). Structure and expression of class II defective herpes simplex virus genomes encoding infected cell polypeptide number 8. J Virol 43, 574-593.
98. Kwong AD, and Frenkel N (1985). The herpes simplex virus amplicon. IV. Efficient expression of a chimeric chicken ovalbumin gene amplified within defective virus genomes. Virology 142, 421-425.
99. Spaete RR, and Frenkel N (1982). The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30, 295-304.
100. Preston CM (1979). Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK. J Virol 29, 275-284.
101. Geller AI, and Breakefield XO (1988). A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241, 1667-1669.
102. Paterson T, and Everett RD (1990). A prominent serine-rich region in Vmw175, the major transcriptional regulator protein of herpes simplex virus type 1, is not essential for virus growth in tissue culture. J Gen Virol 71, 1775-1783.
103. Davidson I, and Stow ND (1985). Expression of an immediate early polypeptide and activation of a viral origin of DNA replication in cells containing a fragment of herpes simplex virus DNA. Virology 141, 77-88.
104. Geller AI, Keyomarsi K, Bryan J, and Pardee AB (1990). An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 87, 8950-8954.
105. McCarthy AM, McMahan L, and Schaffer PA (1989). Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient. J Virol 63, 18-27.
106. Smith IL, Hardwicke MA, and Sandri-Goldin RM (1992). Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 186, 74-86.
107. Lim F, Hartley D, Starr P, Lang P, Song S, Yu L, Wang Y, and Geller AI (1996). Generation of high-liter defective HSV-1 vectors using an IE 2 deletion mutant and quantitative study of expression in cultured cortical cells. Biotechniques 20, 460-469.
108. Berthomme H, Fournel S, and Epstein AL (1996). Increased transcomplementation properties of plasmids carrying HSV-1 origin of replication and packaging signals. Virology 216, 437-443.
109. Pechan PA, Fotaki M, Thompson RL, Dunn R, Chase M, Chiocca EA, and Breakefield XO (1996). A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Hum Gene Ther 7, 2003-2013.
110. Pechan PA, Herrlinger U, Aghi M, Jacobs A, and Breakefield XO (1999). Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. J Gene Med. 1, 176-185.
111. Cunningham C, and Davison AJ (1993). A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 197, 116-124.
112. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, and Geller AI (1996). Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 70, 7190-7197.
113. Aboody-Guterman KS, Pechan PA, Rainov NG, Sena-Esteves M, Jacobs A, Snyder EY, Wild P, Schraner E, Tobler K, Breakefield XO, and Fraefel C (1997). Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo. NeuroReport 8, 3801-3808.
114. Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, and Majzoub JA (1997). Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 3, 813-825.
115. Fraefel C, Breakefield XO, and Jacoby DR (1998). HSV-1 Amplicon. In: Gene Therapy for Neurological Disorders and Brain Tumors. Chiocca EA, Breakefield XO (Eds.). Humana Press, Totowa, NJ, pp. 63-82.
116. Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, and Breakefield XO (1997). HSV/ AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 8, 359-370.
117. Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, and Fraefel C (1998). Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 9, 2787-2794.
118. Saeki Y, and Fraefel C (1999). Herpes Simplex Virus Type 1-Based Amplicon and Hybrid Amplicon Vector Systems. In: Viral Vectors: Basic Science and Gene Therapy. Cid-Arregui A, Garcia A (Eds.). BioTechniques Books, Natick, in press.
119. Stavropoulos TA, and Strathdee CA (1998). An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 72, 7137-7143.
120. Ho DY, Mocarski ES, and Sapolsky RM (1993). Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene. Proc Natl Acad Sci USA 90, 3655-3659.
121. Smith RL, Geller AI, Escudero KW, and Wilcox CL (1995). Long-term expression in sensory neurons in tissue culture from herpes simplex virus type 1 (HSV-1) promoters in an HSV-1-derived vector. J Virol 69, 4593-4599.
122. Jin BK, Belloni M, Conti B, Federoff HJ, Starr R, Son JH, Baker H, and Joh TH (1996). Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Hum Gene Ther 7, 2015-2024.
123. Kaplitt MG, Kwong AD, Kleopoulos SP, Mobbs CV, Rabkin SD, and Pfaff DW (1994). Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc Natl Acad Sci USA 91, 8979-8983.
124. Balague C, Kalla M, and Zhang WW (1997). Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 71, 3299-3306.
125. Flotte TR, Afione SA, and Zeitlin PL (1994). Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 11, 517-521.
126. Kotin RM, Linden RM, and Berns KI (1992). Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 11, 5071-5078.
127. Linden RM, Ward P, Giraud C, Winocour E, and Berns KI (1996). Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 93, 11288-11294.
128. Russell DW, Miller AD, and Alexander IE (1994). Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 91, 8915-8919.
129. Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K, and Natsoulis G (1997). Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 71, 7951-7959.
130. Constantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, and lsacson O (1999). Gene transfer to the nigrostriatal system by hybrid HSV/AAV amplicon vectors. Hum Gene Ther, in press.
131. Gahn TA, and Schildkraut CL (1989). The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell 58, 527-535.
132. Middleton T, and Sugden B (1994). Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J Virol 68, 4067-4071.
133. Sun TQ, Livanos E, and Vos JM (1996). Engineering a mini-herpesvirus as a general strategy to transduce up to 180 kb of functional self-replicating human mini-chromosomes. Gene Ther 3, 1081-1088.
134. Wohlgemuth JG, Kang SH, Bulboaca GH, Nawotka KA, and Calos MP (1996). Long-term gene expression from autonomously replicating vectors in mammalian cells. Gene Ther 3, 503-512.
135. Yates J, Warren N, Reisman D, and Sugden B (1984). A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 81, 3806-3810.
136. Wang S, and Vos JM (1996). A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol 70, 8422-8430.
137. Wang S, Di S, Young WB, Jacobson C, and Link CJJ (1997). A novel herpesvirus amplicon system for in vivo gene delivery. Gene Ther 4, 1132-1141.
138. Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, and Breakefield XO (1999). Single-step conversion of cells to retrovirus vector producers with HSV/EBV hybrid amplicons. J Virol, in press.
139. Battleman DS, Geller AI, and Chao MV (1993). HSV-1 vector-mediated gene transfer of the human nerve growth factor receptor p75hNGFR defines high-affinity NGF binding. J Neurosci 13, 941-951.
140. Neve RL, Ivins KJ, Benowitz LI, During MJ, and Geller AI (1991). Molecular analysis of the function of the neuronal growth-associated protein GAP-43 by genetic intervention. Mol Neurobiol 5, 131-141.
141. Bergold PJ, Casaccia-Bonnefil P, Zeng XL, and Federoff HJ (1993). Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor. Proc Natl Acad Sci USA 90, 6165-6169.
142. Ho DY, Saydam TC, Fink SL, Lawrence MS, and Sapolsky RM (1995). Defective herpes simplex virus vectors expressing the rat brain glucose transporter protect cultured neurons from necrotic insults. J Neurochem 65, 842-850.
143. Geschwind MD, Hartnick CJ, Liu W, Amat J, Van De Water TR, and Federoff HJ (1996). Defective HSV-1 vector expressing BDNF in auditory ganglia elicits neurite outgrowth: model for treatment of neuron loss following cochlear degeneration. Hum Gene Ther 7, 173-182.
144. Garrido JJ, Alonso MT, Lim F, Carnicero E, Giraldez F, and Schimmang T (1998). Defining responsiveness of avian cochlear neurons to brain-derived neurotrophic factor and nerve growth factor by HSV-1-mediated gene transfer. J Neurochem 70, 2336-2346.
145. Lawrence MS, Ho DY, Dash R, and Sapolsky RM (1995). Herpes simplex virus vectors overexpressing the glucose transporter gene protect against seizure-induced neuron loss. Proc Natl Acad Sci USA 92, 7247-7251.
146. Lawrence MS, Sun GH, Kunis DM, Saydam TC, Dash R, Ho DY, Sapolsky RM, and Steinberg GK (1996). Over-expression of the glucose transporter gene with a herpes simplex viral vector protects striatal neurons against stroke. J Cereb Blood Flow Metab 16, 181-185.
147. Lawrence MS, McLaughlin JR, Sun GH, Ho DY, McIntosh L, Kunis DM, Sapolsky RM, and Steinberg GK (1997). Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. J Cereb Blood Flow Metab 17, 740-744.
148. Linnik MD, Zahos P, Geschwind MD, and Federoff HJ (1995). Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 26, 1670-1674.
149. During MJ, Naegele JR, O'Malley KL, and Geller AI (1994). Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266, 1399-1403.
150. Brooks AI, Muhkerjee B, Panahian N, Cory-Slechta D, and Federoff HJ (1997). Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of cre recombinase. Nat Biotechnol 15, 57-62.
151. Huang Q, Vonsattel JP, Schaffer PA, Martuza RL, Breakefield XO, and DiFiglia M (1992). Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Exp Neurol 115, 303-316.
152. Wood MJ, Bymes AP, Kaplitt MG, Pfaff DW, Rabkin SD, and Charlton HM (1994). Specific patterns of defective HSV-1 gene transfer in the adult central nervous system: implications for gene targeting. Exp Neurol 130, 127-140.
153. Ho DY, Fink SL, Lawrence MS, Meier TJ, Saydam TC, Dash R, and Sapolsky RM (1995). Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects. J Neurosci Methods 57, 205-215.
154. Pakzaban P, Geller AI, and Isacson O (1994). Effect of exogenous nerve growth factor on neurotoxicity of and neuronal gene delivery by a herpes simplex amplicon vector in the rat brain. Hum Gene Ther 5, 987-995.
155. Wood MJ, Bymes AP, Pfaff DW, Rabkin SD, and Charlton HM (1994). Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Ther 1, 283-291.
156. Wood MJ, Byrnes AP, Rabkin SD, Pfaff DW, and Charlton HM (1994). Immunological consequences of HSV-1-mediated gene transfer into the CNS. Gene Ther 1 (suppl 1), S82.
157. Jacobs A, Jacoby DR, Sena-Esteves M, Aghi M, Herrlinger U, Wang S, Johnston KM, Aboody-Guterman KS, Fraefel C, and Breakefield XO (1999). Gene delivery by helper virus-free defective herpes viral vectors. J Gene Med. 01, 66.
158. Brooks AI, Halterman MW, Chadwick CA, Davidson BL, Haak-Frendscho M, Radel C, Porter C, and Federoff HJ (1998). Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector. J Neurosci Methods 80, 137-147.
159. Voges J, Reszka R, Sturm V, Jacobs A, and Heiss WD (1998). Stereotactic intracerebral catheter implantation and continuous intratumoral infusion of the liposome associated HSV-tk gene in patients with recurrent, unresectable glioblastoma multiforme - Clinical protocol for a phase I/II study. Keystone.
160. Moriuchi S, Oligino T, Krisky D, Marconi P, Fink D, Cohen J, and Glorioso JC (1998). Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res 58, 5731-5737.
161. Miyatake S, Martuza RL, and Rabkin SD (1997). Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 4, 222-228.
162. Toda M, Martuza RL, Kojima H, and Rabkin SD (1998). In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 160, 4457-4464.
163. Spear MA, Herrlinger U, Rainov N, Pechan P, Weissleder R, and Breakefield XO (1998). Targeting gene therapy vectors to CNS malignancies. J Neurovirol 4, 133-147.
164. Laquerre S, Anderson DB, Stolz DB, and Glorioso JC (1998). Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol 72, 9683-9697.
165. Spear M, Schuback D, Sun F, Brandt CR, and Breakefield XO (1999). HSV-1 gC modified with his-tag replacing heparan sulfate binding domain is expressed in an HSV-1 amplicon vector targeting system. ASGT.
166. Bilbao G, Gomez-Navarro J, and Curiel DT (1998). Targeted adenoviral vectors for cancer gene therapy. Adv Exp Med Biol 451, 365-374.
167. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, and Curiel DT (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72, 9706-9713.
168. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, and Curiel DT (1998). Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 72, 1844-1852.
169. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, and Curiel DT (1998). Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 58, 5738-5748.
170. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, and Curiel DT (1996). Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 14, 1574-1578.
171. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Baird A, Campain JA, and Curiel DT (1997). Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 57, 1447-1451.
172. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, and McCormick F (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
173. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, and zur Hansen H (1998). Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72, 9470-9478.
174. Brenner M (1994). Structure and transcriptional regulation of the GFAP gene. Brain Pathol 4, 245-257.
175. McKie EA, Graham DI, and Brown SM (1998). Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector - potential glioblastoma targeting. Gene Ther 5, 440-450.
176. Chung RY, Saeki Y, and Chiocca EA (1999). B-myb promoter retargeting of herpes simplex virus' γ34.5-mediated virulence towards tumor and cycling cells. J Virol, submitted.
177. Adams PD, and Kaelin WGJ (1995). Transcriptional control by E2F. Semin Cancer Biol 6, 99-108.
178. Sellers WR, and Kaelin WGJ (1997). Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 15, 3301-3312.
179. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WGJ, and Fine HA (1997). Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3, 1145-1149.
180. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, and Harris AL (1997). Targeting gene expression to hypoxic tumor cells. Nat Med 3, 515-520.
181. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, and Weichselbaum RR (1995). Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1, 786-791.
182. Sadowski I, Ma J, Triezenberg S, and Ptashne M (1988). GAL4-VP16 is an unusually potent transcriptional activator. Nature 335, 563-564.
183. Axelrod JD, Reagan MS, and Majors J (1993). GAL4 disrupts a repressing nucleosome during activation of GAL1 transcription in vivo. Genes Dev 7, 857-869.
184. Fink DJ, Poliani PL, Oligino T, Krisky DM, Goins WF, and Glorioso JC (1997). Development of an HSV-based vector for the treatment of Parkinson's disease. Exp Neurol 144, 103-121.
185. Oligino T, Poliani PL, Marconi P, Bender MA, Schmidt MC, Fink DJ, and Glorioso JC (1996). In vivo transgene activation from an HSV-based gene therapy vector by GAL4:vp16. Gene Ther 3, 892-899.
186. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, and O'Malley BW (1992). The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69, 703-713.
187. Wang Y, O'Malley BWJ, Tsai SY, and O'Malley BW (1994). A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 91, 8180-8184.
188. Oligino T, Poliani PL, Wang Y, Tsai SY, O'Malley BW, Fink DJ, and Glorioso JC (1998). Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther 5, 491-496.
189. Baron U, Gossen M, and Bujard H (1997). Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res 25, 2723-2729.
190. Freundlieb S, Baron U, Bonin AL, Gossen M, and Bujard H (1997). Use of tetracycline-controlled gene expression systems to study mammalian cell cycle. Methods Enzymol 283, 159-173.
191. Gossen M, and Bujard H (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89, 5547-5551.
192. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, and Bujard H (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.
193. Ho DY, McLaughlin JR, and Sapolsky RM (1996). Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system. Brain Res Mol Brain Res 41, 200-209.
194. Fotaki ME, Pink JR, and Mous J (1997). Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer. Gene Ther 4, 901-908.
195. Herrlinger U, Pechan P, Jacobs A, Woiciechowski Ch, Rainov N, Fraefel C, Paulus W, and Breakefield XO (1999). HSV-1 infected-cell proteins influence the expression of a tetracycline-regulated transgene. Hum Gene Ther, submitted.
196. Barnett FH, Rainov NG, Ikeda K, Schuback DE, Elliott P, Kramm CM, Chase M, Qureshi NH, Harsh G, Chiocca EA, and Breakefield XO (1999). Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther 6, 14-20.
197. Muldoon LL, Nilaver G, Kroll RA, Pagel MA, Breakefield XO, Chiocca EA, Davidson BL, Weissleder R, and Neuwelt EA (1995). Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol 147, 1840-1851.
198. Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, and Neuwelt EA (1995). Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA 92, 9829-9833.
199. Rainov NG, Zimmer C, Chase M, Kramm CM, Chiocca EA, Weissleder R, and Breakefield XO (1995). Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther 6, 1543-1552.
200. Rainov NG, Dobberstein KU, Heidecke V, Dorant U, Chase M, Kramm CM, Chiocca EA, and Breakefield XO (1998). Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Ther 5, 158-162.
201. Aboody K, Rainov NG, Small JE, Liu S, Bower KA, Herrlinger U, Black P, Breakefield XO, and Snyder EY (1999). Neural stem cells migrate throughout and express foreign genes within experimental gliomas - a potential gene therapy approach to brain tumors. Nat Med, submitted.
202. Herrlinger U, Woiciechowski Ch, Aboody-Guterman K, Jacobs A, Rainov N, Snyder EY, and Breakefield XO (1999). C17-2 neural progenitor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Gene Ther, submitted.